{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:08:19Z","timestamp":1770822499575,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,7,14]],"date-time":"2010-07-14T00:00:00Z","timestamp":1279065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s10549-010-1029-2","type":"journal-article","created":{"date-parts":[[2010,7,13]],"date-time":"2010-07-13T04:19:24Z","timestamp":1278994764000},"page":"553-561","source":"Crossref","is-referenced-by-count":89,"title":["HER2 status in a population-derived breast cancer cohort: discordances during tumor progression"],"prefix":"10.1007","volume":"125","author":[{"given":"Ulla","family":"Wilking","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambert","family":"Skoog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hatschek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Lidbrink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran","family":"Elmberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemming","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,14]]},"reference":[{"key":"1029_CR1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1634\/theoncologist.8-4-307","volume":"8","author":"SJ Ross","year":"2003","unstructured":"Ross SJ, Fletcher JA, Linette GP (2003) The HER-2\/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307\u2013325","journal-title":"Oncologist"},{"issue":"4785","key":"1029_CR2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2\/neu oncogene. Science 235(4785):177\u2013182","journal-title":"Science"},{"issue":"11","key":"1029_CR3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"44","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shalk S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2\/neu\/NEU for metastatic breast cancer that overexpresses HER2\/neu\/NEU. N Engl J Med 44(11):783\u2013792","journal-title":"N Engl J Med"},{"key":"1029_CR4","unstructured":"Marty M, Cognetti F, Maraninchi D et al (2001) Randomised phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor-2 positive metastatic breast cancer administered as first line treatment: the M77001 study group. J Clin Oncol 9: 4265\u20134274"},{"key":"1029_CR5","doi-asserted-by":"crossref","unstructured":"Slamon D, Eiermann W, Robert N, Pienowski T, Martin M, Rolski J et al (2009) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC\u00a0\u2192\u00a0T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC\u00a0\u2192\u00a0TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. SABCS (abstract 62)","DOI":"10.1158\/0008-5472.SABCS-09-62"},{"key":"1029_CR6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1080\/02841860902862511","volume":"48","author":"L Ryden","year":"2009","unstructured":"Ryden L, Haglund M, Bendahl P et al (2009) Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer\u2014a national survey performed at pathology departments in Sweden. Acta Oncol 48:860\u2013866","journal-title":"Acta Oncol"},{"key":"1029_CR7","first-page":"26","volume":"44","author":"R MacFarlane","year":"2008","unstructured":"MacFarlane R, Speers C, Masoudi H et al (2008) Molecular change in the primary breast cancer versus the relapsed\/metastatic lesion from a large population based database and tissue micro array series. Proc Am Soc Clin Oncol 44:26 (abstract 1000)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"1029_CR8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10549-008-9931-6","volume":"113","author":"EE Lower","year":"2009","unstructured":"Lower EE, Glass E (2009) Blau B HER-2\/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113:301\u2013306","journal-title":"Breast Cancer Res Treat"},{"key":"1029_CR9","doi-asserted-by":"crossref","unstructured":"Liedtke C, Broglio K, Moulder S et al (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (e-print)","DOI":"10.1093\/annonc\/mdp263"},{"issue":"25","key":"1029_CR10","doi-asserted-by":"crossref","first-page":"9393","DOI":"10.1073\/pnas.0402993101","volume":"101","author":"S Meng","year":"2004","unstructured":"Meng S, Tripathy D, Shete S et al (2004) HER-2 gene amplification can be acquired as breast cancer progresses. PNAS 101(25):9393\u20139398","journal-title":"PNAS"},{"key":"1029_CR11","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1001\/jama.291.16.1972","volume":"291","author":"H Yaziji","year":"2004","unstructured":"Yaziji H, Goldstein LC, Barry TS et al (2004) HER2 amplification ratios in breast cancer using parallel tissue based methods. JAMA 291:1972\u20131977","journal-title":"JAMA"},{"issue":"36","key":"1029_CR12","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1200\/JCO.2004.01.0454","volume":"23","author":"L McShane","year":"2005","unstructured":"McShane L, Altman D, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067\u20139072","journal-title":"J Clin Oncol"},{"issue":"2","key":"1029_CR13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2307\/2529786","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 33(2):363\u2013374","journal-title":"Biometrics"},{"key":"1029_CR14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","volume":"69","author":"D Schoenfeld","year":"1982","unstructured":"Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69:239\u2013241","journal-title":"Biometrika"},{"issue":"23","key":"1029_CR15","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-09-1735","volume":"15","author":"E Mittendorf","year":"2009","unstructured":"Mittendorf E, Wu Y, Scaltriti M et al (2009) Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15(23):7381\u20137388","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1029_CR16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1023\/A:1019601022456","volume":"75","author":"T Fehm","year":"2002","unstructured":"Fehm T, Gebauer G, J\u00e4ger W (2002) Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res Treat 75(2):97\u2013106","journal-title":"Breast Cancer Res Treat"},{"issue":"1B","key":"1029_CR17","first-page":"647","volume":"26","author":"D Pectasides","year":"2006","unstructured":"Pectasides D, Gaglia A (2006) HER2\/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 26(1B):647\u2013653","journal-title":"Anticancer Res"},{"key":"1029_CR18","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdf252","volume":"13","author":"D Gancberg","year":"2002","unstructured":"Gancberg D, Di Leo A, Cardoso F et al (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13:1036\u20131043","journal-title":"Ann Oncol"},{"key":"1029_CR19","doi-asserted-by":"crossref","unstructured":"Franco A, Col N (2004) Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: a meta-analysis. In: Perry M (ed) 40th annual meeting of the ASCO, New Orleans, LA, 11 pp (abstract 539)","DOI":"10.1200\/jco.2004.22.90140.539"},{"key":"1029_CR20","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/bcr1366","volume":"8","author":"E Munzone","year":"2006","unstructured":"Munzone E, Curigliano G, Rocca A et al (2006) Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 8:R4","journal-title":"Breast Cancer Res"},{"issue":"2","key":"1029_CR21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/cncr.21202","volume":"104","author":"A Lipton","year":"2005","unstructured":"Lipton A, Leitzel K, Ali SM et al (2005) Serum HER-2\/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104(2):257\u2013263","journal-title":"Cancer"},{"issue":"21","key":"1029_CR22","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2000.18.21.3651","volume":"18","author":"G Pauletti","year":"2000","unstructured":"Pauletti G, Danekar RongH et al (2000) Assessment of methods for tissues-based detection of the HER-2\/neu alteration in human breast cancer: direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18(21):3651\u20133664","journal-title":"J Clin Oncol"},{"issue":"11","key":"1029_CR23","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/94.11.855","volume":"94","author":"PC Roche","year":"2002","unstructured":"Roche PC, Suman VJ, Jenkins RB et al (2002) Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94(11):855\u2013857","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1029_CR24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolf","year":"2007","unstructured":"Wolf AC (2007) American society of clinical oncology\/college of American pathologists guideline\u00a0<\u00a0recommendations for human epidermal growth receptor 2 testing in breast cancer. J Clin Oncol 25(1):118\u2013145","journal-title":"J Clin Oncol"},{"issue":"7","key":"1029_CR25","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1158\/1078-0432.CCR-07-4082","volume":"14","author":"JM Wu","year":"2008","unstructured":"Wu JM, Fackler MJ, Halushka MK et al (2008) Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14(7):1938\u20131946","journal-title":"Clin Cancer Res"},{"key":"1029_CR26","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/annonc\/mdn021","volume":"19","author":"PH Cottu","year":"2008","unstructured":"Cottu PH, Asselah J, Lae M et al (2008) Intratumoral heterogeneity of HER-2\/neu expression and its consequences for the management for advanced breast cancer. Ann Oncol 19:596\u2013597","journal-title":"Ann Oncol"},{"issue":"1","key":"1029_CR27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00129039-200403000-00003","volume":"12","author":"J Andersson","year":"2004","unstructured":"Andersson J, Linderholm B, Bergh J, Elmberger G (2004) HER-2\/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl Immunohistochem Mol Morphol 12(1):14\u201320","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"3","key":"1029_CR28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1023\/A:1006453420088","volume":"60","author":"G Ottesen","year":"2000","unstructured":"Ottesen G, Christensen J, Larsen J et al (2000) Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy. Breast Cancer Res Treat 60(3):219\u2013226","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"1029_CR29","first-page":"8317","volume":"61","author":"T Norberg","year":"2001","unstructured":"Norberg T, Klaar S, K\u00e4rf G, Nordgren H, Holmberg L, Bergh J (2001) Increased p53 mutation frequency during tumor progression\u2014results from a breast cancer cohort. Cancer Res 61(22):8317\u20138321","journal-title":"Cancer Res"},{"key":"1029_CR30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nature08489","volume":"461","author":"SP Shah","year":"2009","unstructured":"Shah SP, Morin RD, Khattra J et al (2009) Mutational evolution in a lobular breast cancer tumor profiled at single nucleotide resolution. Nature 461:809\u2013913","journal-title":"Nature"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1029-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-010-1029-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1029-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T22:35:14Z","timestamp":1591482914000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-010-1029-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,14]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1029"],"URL":"https:\/\/doi.org\/10.1007\/s10549-010-1029-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,14]]}}}